Moderna says their COVID vaccine is safe and effective in teens
Biotech company Moderna announced Tuesday that its coronavirus vaccine was shown to be both reliable and effective in guarding against COVID-19 in children as young as 12 years of age.
This is a big deal:
Although children are far less likely than adults to become seriously ill due to COVID-19, they account for about 14% of all coronavirus cases in the United States. According to the American Academy of Pediatrics, at least 316 children have died in the United States alone, per the AP.
Moderna's CEO Stéphane Bancel said via a press release that the biotech firm "will submit these results to the U.S. FDA and regulators globally in early June and request authorization. We remain committed to doing our part to help end the COVID-19 pandemic."
The clinical trial:
The vaccine is 93% effective, commencing 14 days after the first dose and 100% after the second dose.
The Phase 3 trial, known as the TeenCOVE study, enrolled more than 3,700 participants ages 12 to less than 18 years in the U.S.